UCB S.A.
UCB
株式のランク
#525
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
株価
$243.04
時価総額
$46.34B
変化（1日）
0.15%
変化（1年）
-16.16%
国
BE
取引 UCB S.A. (UCB)
カテゴリー
Healthcare
UCB S.A.（UCB）の配当履歴
UCB S.A.（証券コード：UCB）は合計で29回の配当を行いました。
すべての配当の合計（株式分割調整済み）は：$27.69
配当利回り（TTM）：0.0072
すべての配当の合計（株式分割調整済み）は：$27.69
配当利回り（TTM）：0.0072
2000から2026までのUCB S.A.（UCB）の配当履歴
年間配当支払い
| 年 | 配当（株式分割調整済み） | 変化 |
|---|---|---|
| 2026 (TTM) | $1.20 | 0.00% |
| 2025 | $1.20 | -11.98% |
| 2024 | $1.36 | 2.26% |
| 2023 | $1.33 | 2.31% |
| 2022 | $1.30 | 2.36% |
| 2021 | $1.27 | 2.42% |
| 2020 | $1.24 | 2.48% |
| 2019 | $1.21 | 2.54% |
| 2018 | $1.18 | 2.61% |
| 2017 | $1.15 | 4.55% |
| 2016 | $1.10 | 3.77% |
| 2015 | $1.06 | 1.92% |
| 2014 | $1.04 | 1.96% |
| 2013 | $1.02 | 2.00% |
| 2012 | $1.00 | 2.04% |
| 2011 | $0.98 | 2.08% |
| 2010 | $0.96 | 4.35% |
| 2009 | $0.92 | 0.00% |
| 2008 | $0.92 | 2.22% |
| 2007 | $0.9 | 2.27% |
| 2006 | $0.88 | 2.33% |
| 2005 | $0.86 | -34.85% |
| 2004 | $1.32 | 9.09% |
| 2003 | $1.21 | 6.14% |
| 2002 | $1.14 | 78.13% |
| 2001 | $0.64 | 28.00% |
| 2000 | $0.5 | 0.00% |
すべての配当支払いの一覧
| 年 | 配当 | 変化 |
|---|---|---|
| 2026 (TTM) | $1.20 | 0.00% |
| 2025 | $1.20 | -11.98% |
| 2024 | $1.36 | 2.26% |
| 2023 | $1.33 | 2.31% |
| 2022 | $1.30 | 2.36% |
| 2021 | $1.27 | 2.42% |
| 2020 | $1.24 | 2.48% |
| 2019 | $1.21 | 2.54% |
| 2018 | $1.18 | 2.61% |
| 2017 | $1.15 | 4.55% |
| 2016 | $1.10 | 3.77% |
| 2015 | $1.06 | 1.92% |
| 2014 | $1.04 | 1.96% |
| 2013 | $1.02 | 2.00% |
| 2012 | $1.00 | 2.04% |
| 2011 | $0.98 | 2.08% |
| 2010 | $0.96 | 4.35% |
| 2009 | $0.92 | 0.00% |
| 2008 | $0.92 | 2.22% |
| 2007 | $0.9 | 2.27% |
| 2006 | $0.88 | 2.33% |
| 2005 | $0.86 | -34.85% |
| 2004 | $1.32 | 9.09% |
| 2003 | $1.21 | 6.14% |
| 2002 | $1.14 | 78.13% |
| 2001 | $0.64 | 28.00% |
| 2000 | $0.5 | 0.00% |
同業他社や競合企業の配当履歴
| 企業 | 配当支払い回数 | 国 |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
